Enhertu Snub From England’s NICE Not ‘In Line’ With Other Countries

England’s NICE has “misclassified” HER2-low metastatic breast cancer as a medium severity disease, say AstraZeneca and Daiichi Sankyo, the co-developers of Enhertu. NICE said it would consider a rapid re-appraisal if the companies offered a “fair price” for the drug.

Outlier — NICE's decision on Enhertu is different from that of many other countries • Source: Shutterstock

Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate drug used to treat certain types of breast cancer, has been turned down for English funding in a new indication after the country’s health technology assessment (HTA) body NICE said its co-developers were “unwilling” to offer the drug at a lower price.

The indication for which NICE rejected the reimbursement of Enhertu was HER2-low metastatic breast cancer. It is already available for...